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Background: The role of community pharmacists in disease state management has been mooted for some years.
Despite a number of trials of disease state management services, there is scant literature into the engagement of,
and with, pharmacists in such trials. This paper reports pharmacists’ feedback as providers of a Pharmacy Asthma
Management Service (PAMS), a trial coordinated across four academic research centres in Australia in 2009. We also
propose recommendations for optimal involvement of pharmacists in academic research.
Methods: Feedback about the pharmacists’ experiences was sought via their participation in either a focus group
or telephone interview (for those unable to attend their scheduled focus group) at one of three time points. A
semi-structured interview guide focused discussion on the pharmacists’ training to provide the asthma service, their
interactions with health professionals and patients as per the service protocol, and the future for this type of
service. Focus groups were facilitated by two researchers, and the individual interviews were shared between three
researchers, with data transcribed verbatim and analysed manually.
Results: Of 93 pharmacists who provided the PAMS, 25 were involved in a focus group and seven via telephone
interview. All pharmacists approached agreed to provide feedback. In general, the pharmacists engaged with both
the service and research components, and embraced their roles as innovators in the trial of a new service. Some
experienced challenges in the recruitment of patients into the service and the amount of research-related
documentation, and collaborative patient-centred relationships with GPs require further attention. Specific service
components, such as the spirometry, were well received by the pharmacists and their patients. Professional rewards
included satisfaction from their enhanced practice, and pharmacists largely envisaged a future for the service.
Conclusions: The PAMS provided pharmacists an opportunity to become involved in an innovative service delivery
model, supported by the researchers, yet trained and empowered to implement the clinical service throughout the
trial period and beyond. The balance between support and independence appeared crucial in the pharmacists’
engagement with the trial. Their feedback was overwhelmingly positive, while useful suggestions were identified
for future academic trials.
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For some decades, there has been a recognised, and in-
creasing, need for community pharmacists to demon-
strate their expertise in healthcare delivery, including,
but no longer limited to, medication management. This
role uniquely positions pharmacists as intermediaries be-
tween patients and prescribers, yet practising independ-
ently from prescribers, with roles incorporating
medication review, case identification and disease moni-
toring, patient education and advocacy, and referral to
prescribers and other health professionals.
Roles for community pharmacists as medication and
disease state management experts have been reflected in
the development of specialist services delivered within
pharmacies. Patients with chronic medical conditions
are particularly well suited to receive such services from
pharmacists, due to their need for ongoing monitoring
and management of (often) multiple medications. To
this end, services based on the management of asthma
[1-7], diabetes [8,9], hypertension [10] and bodyweight
[11] have been tested, with positive clinical [1,3,5-9] and
economic [4,6,7,9] impact data.
The successful establishment of new services requires
rigorous programs of evaluation. Pharmacists wishing to
develop expertise in chronic disease management, and
subsequently deliver a useful, sustainable, economically
viable and professionally rewarding service, have been
encouraged to participate in academic trials of specialist
services. The researchers commonly provide advanced
clinical education, skills training, practical support to es-
tablish and deliver the service, and feedback on service
standards and patient outcomes. Participating pharma-
cists also stand to benefit from peer support of collea-
gues and other health care professionals who have been
informed of the trial and, in funded projects, potentially
receive financial compensation for their time
commitment.
Previously, we have investigated the motivation for
pharmacists to participate in research trials; [12] how-
ever, uptake of professional services requires commit-
ment beyond the period of the research program.
Reports from completed trials suggest that pharmacists
may find the implementation and delivery of a specialist
service a significant leap beyond their everyday practice.
[10,13,14]
Consistent with the theory on the diffusion of
innovation [14,15], the pharmacists accepting the chal-
lenge of trialling a new cognitive service may be consid-
ered “innovators” and/or “early adopters”. However, the
profession needs to move beyond this early phase if ser-
vices are to be sustainable and accepted by both patients
and pharmacists in practice. Research promoting the im-
plementation of professional services has provided guid-
ance on human resources, communication andteamwork, and external support for the service [14],
while reports following the implementation of services
often focus on the patient outcomes, rather than the
pharmacists’ experiences as providers of a service [16].
Despite the emergence of a number of specialist disease-
management services in pharmacies, there has been little
published research to explore pharmacists’ experiences
as pioneers of a structured disease state management
service, in balancing the additional workload involved in
service provision, learning and applying new skills, man-
aging documentation requirements, marketing them-
selves in a different context, and in developing new
relationships [13,17]. Internationally, Canadian research-
ers have reported common challenges in pharmacists’
engagement with disease state management services, in-
cluding time constraints, access to information, forma-
tion of working relationships and absence of a practice
model [18]. Whether these are universal depends on the
program under study and constraints of each country’s
healthcare system.
Thus, it is important to explore the barriers and facili-
tators from the perspective of the service provider, the
pharmacist. This paper reports the exploration of phar-
macists’ experiences as service providers in an imple-
mentation trial of a novel patient-focused specialist
asthma service (the Pharmacy Asthma Management Ser-
vice, PAMS) in Australia [3]. In addition, we sought their
views on how their patients received the service, the
pharmacists’ interactions with other health care profes-
sionals (particularly general practitioners), as a result of
the asthma service, the impact of the service on their
role, their opinions on offering such a service in future,
and feedback on the support from the investigators to
guide the service implementation.
The objective of this study was to gain feedback from
the participating pharmacists on their experiences as
providers of the specialist asthma service. A second ob-
jective, based on the results of these data, was to
propose recommendations for optimal involvement of
pharmacists in a multi-centre academic research trial of
this nature. Based on the researchers’ experience with
the original randomised controlled trial of this service
[5] and a similar service for diabetes management by
pharmacists in Australia, [13] it was hypothesised that
the model for our trial, offering support, guidance and
motivation for the participating pharmacists, would gen-
erate mostly positive experiences amongst the pharma-
cists and would facilitate constructive feedback about
the research protocol from the participants to the
researchers.
Methods
This implementation trial was conducted as a cluster
randomised controlled study comparing the original
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with a less-intensive model of three visits in six months.
Recruitment of the service providers was undertaken
geographically by pharmacy, with proportional represen-
tation of the number of community pharmacies in re-
gional and metropolitan areas in four States/Territories
in Australia (New South Wales, Victoria, Queensland
and the Australian Capital Territory). The recruitment
was managed online by The Pharmacy Guild of Austra-
lia, as part of the research funding agreement. Pharmacy
eligibility criteria were the availability of one pharmacist
to attend training for credentialing as the service pro-
vider, a private consultation space, and availability of a
second pharmacist or time outside normal hours to pro-
vide uninterrupted appointments for the service. The
pharmacists received advanced training in asthma man-
agement over two days at each research centre; prior to
this, they all undertook self-directed study using pro-
vided reading materials. Training incorporated risk as-
sessment, pathophysiology of asthma, asthma
medications, current treatment guidelines, [19] patient
education, goal setting, adherence assessment, and spir-
ometry. The training concluded with an examination of
both knowledge and skills, with successful completion
awarded accreditation by the Australian Association of
Consultant Pharmacy. Following training, a total of 106
pharmacists were authorised to commence the asthma
management service, and 93 proceeded to provide the
service.
Key features of this pharmacy asthma service were
derived from the original randomised control trial of the
service [5]. Each pharmacist recruited up to 10 regular
customers of their pharmacy who were identified as
being at risk of poor asthma outcomes, either by having
sub-optimally-controlled asthma or no asthma review in
the previous six months [2]. Pharmacists had two to
three months to complete recruitment, and progress was
monitored and encouragement provided approximately
three weeks after the training. A median of five patients
per pharmacy completed the service (range 0–10).
Patients attended either three or four visits at their phar-
macy over a six-month period in 2009 where spirometry
and asthma control were measured, with the consulta-
tions focusing on asthma control and factors influencing
asthma control, smoking cessation (where warranted),
medication use, action plan ownership, inhaler technique
and goal setting. The initial patient consultation required
completion of several validated questionnaires by the pa-
tient, with further questionnaires at subsequent visits
(partial data were included in the case of patients with-
drawing from the service). Further, the pharmacists
maintained research-related documentation, including
records of their clinical interventions, patients’ spirom-
etry readings, and communication with patients andother healthcare providers. General practitioners (GPs)
in the area surrounding each study pharmacy were sent
information about the study by the investigators, and the
pharmacists were encouraged to contact, and preferably
meet with, their local GPs to explain the service. Phar-
macists were trained in mechanisms to refer patients to
their GP for issues such as medication changes, subopti-
mal spirometry values and provision of written action
plan; a template for referral and an asthma action plan
was provided within the patient file.
The study was conducted in accordance with the Hel-
sinki Declaration, and the study protocol was approved
by the Human Research Ethics Committee of The Uni-
versity of Sydney (11-2008/11419), with secondary
approvals from the Medical Research Ethics Committee
of The University of Queensland, the Human Research
Ethics Committee of Charles Sturt University, and the
Monash University Human Research Ethics Committee.
All pharmacists and patients provided written informed
consent for their participation. Pharmacists were not
compensated for their time in providing reflective data,
although their time spent with study patients was
remunerated via payments approved in the research
protocol.
Feedback was sought from participating pharmacists
at three time points (Table 1), to facilitate reflection as
the project progressed. The data were obtained using
focus groups, supplemented by individual interviews for
those unavailable for their scheduled focus group. Phar-
macists were sampled randomly from rural and urban
pharmacies, and individuals participated at only one
time point, to minimise their research load. The aim was
to recruit six to eight pharmacists for each focus group.
Focus groups of this size have been established as opti-
mal to encourage contribution of each participant and
to compare and contrast their experiences [20].
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phone after business hours, for the convenience of parti-
cipants and to facilitate interaction in the focus groups
between geographically distanced pharmacists. A semi-
structured interview guide, based on previous research
experience, was developed (Additional file 1), with ques-
tions centred around pharmacists’ views on their train-
ing for the service, their perceptions regarding their
patients’ experience of receiving the service, interactions
with health professionals, and the future for a service
model such as this. All focus groups were facilitated by
two investigators from the main research centre. The in-
dividual interviews were shared between three inter-
viewers from the main research centre, who were
trained in a consistent approach. In cases where the
interviewer/facilitator was not known to the pharmacist,
rapport was established prior to the discussion via intro-
duction to the researcher and general conversation
about pharmacy practice, and an overview of how the
focus group discussions would unfold.
Interviews and focus group discussions were tran-
scribed verbatim by professional transcribers independ-
ent to the research team. The transcripts were analysed
manually for the identification of underlying concepts by
one researcher in accordance with the semi-structured
focus group guide, with consensus then achieved by two
more investigators for interpretation of the content.
Comments were extracted as both confirmative and dis-
confirmative evidence to explore the breadth of
responses and pharmacists’ experiences.
Results
All pharmacists approached to give feedback agreed;
however, in a small number of cases, the pharmacist
could not commit to attending the focus group. Overall,
32 pharmacists were involved in either a focus group or
individual interview (Table 1): seven following comple-
tion of at least one patient’s initial consultation (“Early”,
quotations annotated “FG1”), 18 after completion of the
service (“End”, quotations annotated “FG2” and “I2”),
and seven six months after service completion (“Follow-
up”, quotations annotated “FG3” and “I3”). Eight con-
cepts relating to the service provision were identified
from the transcript analysis: the training, challenges with
the recruitment and consultation of patients, the service
components, logistics of the service provision, relation-
ships with the GPs, perceptions of the patients’ experi-
ences, professional rewards, and the future of the
service.
The training
The clinical and practical skills training in asthma man-
agement was perceived to train pharmacists to a high
standard:“My husband’s a GP, and he looked through the course
and what we learnt, and he said we’re better qualified
than most GPs now to handle asthma.” (FG3-1)
Training in spirometry was described by one partici-
pant as “probably the pinnacle part that you want to
take away from that day” (FG1-4), and there were
requests for greater emphasis on this section to improve
pharmacists’ confidence, exemplified by the pharmacist
who was “dead scared a doctor would ask me, ‘what does
this [spirometry result] mean?’” (FG3-2)
Comments suggested that training group sizes should
be limited to 20 people, as per the size of the groups in
this study, for optimal skills development and peer
support.
Challenges with recruitment of and consultation
with patients
Confidence with recruiting patients was critical to the
patients’ engagement with the service; some pharmacists
found promoting the service daunting and a new experi-
ence, and some requested more training in patient re-
cruitment into this type of clinical service. Key
recruitment strategies were revealed:
“Work out what are the selling points . . . and why is it
good for them to be involved in a university trial, and
what outcomes we’re after . . . and how to hit their
trigger points when you’re recruiting them.” (FG1-6)
“You need to talk to patients at length and allay their
fears and talk about their desires and all that sort of
stuff . . . the time to do this is in the afternoon when
you’ve got the time.” (FG2-N3)
Some pharmacists had no problems reaching their
goal of 10 recruited patients:
“I didn’t really have any trouble getting the 10. They
all stuck through the three visits, but a lot of them
dropped off for the [post-study] follow-up visit.”
(FG3-3)
“The customers really wanted to be part of the
university and they saw it as a privilege.”
(FG1-6)
Pharmacists reflected on their approach to patient re-
cruitment, suggesting that recruitment is a developmen-
tal process, despite their training in how to identify and
approach suitable patients:
“I could've been a lot more careful about whom I
recruited . . . [later] I found candidates who would’ve
benefited more from the program . . . I thought, ‘oh
Emmerton et al. BMC Health Services Research 2012, 12:164 Page 5 of 10
http://www.biomedcentral.com/1472-6963/12/164gosh, I wish I'd made you one of my candidates.’”
(FG3-2)
“I’d probably do it differently if I did it again . . . I did
it by going back through script records to see who
would be suitable, and . . . the ones that I ended up
recruiting . . . probably weren’t the 10 people who
would benefit most from that program . . . I still feel as
though they have all benefited from it, but I think I’d
put a little bit more thought into how I would pick
them out again.” (I2-V4)
A number of the pharmacists found themselves
recruiting mainly older patients into the service, appar-
ently due to their availability and commitment:
“I had around 10 young people who didn’t actually
turn up for their appointments . . . but certainly semi-
retired men and women were perfect.” (FG1-7)
“It was very, very difficult to get working people to
come . . . I had to [consult them] on Saturday
afternoons . . . just a time that they could find to fit me
in.” (FG3-2)
Once recruited, lack of commitment by patients
caused frustration for the pharmacists. Despite remin-
ders, some failed to attend appointments. Patients’ reluc-
tance to persist with the program may have resulted
from the long initial consultation, which involved the
most research documentation. One pharmacist reflected
after the study that the most challenging group to re-
cruit, young males, “probably needed the program the
most” (FG3-2).
Critique of the service components
The pharmacists largely reflected positively on the prac-
tical application of the service. The provision of spirom-
etry was well received by pharmacists, and reportedly,
their patients, providing a unique element to the service.
Some of the pharmacists would have liked to perform
the spirometry earlier in the visit to engage the patient:
“They loved looking at the graphs and trying to
understand what this meant and what that figure
meant . . . trying to get them to use the spirometer in
such a way that they got an ‘A’ quality on their report
. . .They were there to try and beat the machine.”
(I2-N7)
Criticisms of the service components pertained to the
need for more educational aids for patients, a more effi-
cient system to monitor patients’ attainment of their
therapeutic goals, and frustration with the amount and
flow of the research documentation, which was per-
ceived to deter patient continuance:“[The research documentation] needs to be very
careful that it’s not overly clunky, that it’s not too big
and unwieldy. Too big and unwieldy will scare people
away.” (I2-N6)
“Every time I see the package lying on my desk, I just
look through the paperwork and shake my head, and
think . . . whether it was shown to someone who
actually spends their day at the coalface . . . The way
the questionnaires are laid out . . . they just don’t flow
very well . . . maybe you need a sort of panel . . . of
community pharmacists that you can just call on . . .
for a bit of input before things are being finalised.”
(FG3-5)
The pharmacists developed a flexible approach in their
assessment of individuals’ needs within the bounds of
the service:
“Some people love it. They’d come in every month if
you want them to . . . they’re those sort of people that
. . . like other people to be looking after them, whereas
you get the other ones . . . you could spend half an
hour with them and that would be fine.” (I3)
“You had to adjust mentally, I suppose, prioritise the
information you felt that each particular patient
needed . . . You physically can’t give someone 20 pieces
of information.” (FG3-5)
Logistics of service provision
The dominant theme relating to logistics of the service
was the need for the pharmacist to be available to pro-
vide the service. Engaging a locum and/or changing staff
rosters may be necessary to deliver the service:
“I’ve had to try and get a second pharmacist in and
try and schedule the appointments in one after the
other on like a certain morning a week. The hardest
part is trying to free up myself to do it.” (I2-V3)
“It was purely time management for me. I had to
manage my time personally better, and we had a
diary book that we booked people in, because we
would use the [private] room for other things.”
(FG2-V1)
The pharmacists were very conscious of the need to
provide undisturbed consultations, which raised further
issues around workflow, privacy and location of the
consultation.
Relationships with GPs
A feature of the service was the role of the pharmacist
as a both a clinical advisor and intermediary between
patients and GPs. This required awareness of the service
by GPs and communication pathways to propose
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pharmacists reflected on the need for more formalised
and proactive communication strategies with GPs. Phar-
macists’ attempts to communicate directly with GPs to
discuss the service or therapeutic recommendations for
patients were variable, as this is a new type of service in
primary care, and no pharmacist reported any GP-
initiated communication:
“They [GPs] didn’t seem to know anything about it,
despite introductory letters obviously being sent out by
ourselves and also from you [researchers], so there was
a lot of time spent in educating them.” (FG1-3)
“I collected a whole list of local doctors and sent them
letters and tried to get some sort of response, but
unfortunately, none of the GPs really care about this.”
(FG2-N1)
“You try and be diplomatic in how you pitch [the
clinical recommendation] . . . from the point of view of
saying it’s another idea, and you put all of the dot
points down with question marks in front of them,
because obviously there may be information that the
GPs have that you’re not privy to.” (I2-N5)
“Most of my communications to [GPs] about plans are
written, so there’s really no verbal communication.”
(FG2-Q2)
The pharmacists perceived that the underlying issues
were misunderstanding about the service and the poten-
tial threat to GPs’ roles and income stream:
“Not so much resentment, but a misunderstanding.
‘Well, why on earth are you doing this sort of thing?
Why are you interfering with what seems okay to me?’”
(FG3-2)
“He [the GP] was just concerned that because he
hadn’t acted on anything, I was actually going to
report him.” (FG2-Q1)
Successful interventions mediated by contact with GPs
included requests for asthma action plans and medica-
tion changes:
“I actually suggested changes to medication in
probably four or five people. The doctors weren’t at all
perturbed about that. They gave them a go.”
(FG3-2)
“I asked [my patients] to take the written notes to the
doctor next time they visited, which most of them did.”
(FG2-V1)
“I asked for quite a few asthma action plans, and it’s
quite comical the funny little scraps of paper the
patients were given . . . I would’ve hoped for something
a little bit more user friendly.” (FG3-1)Perceptions of the patients’ experiences
Overall, feedback from pharmacists about patients’ ex-
perience of the asthma service was very positive, trans-
lating to enhanced professional pride and relationships
with patients:
“Just that little bit of interaction they have with you on
those visits makes a world of difference. They find you
much more approachable.” (FG1-4)
For many patients, this comprised a new type of inter-
action with their pharmacist, and the pharmacists con-
sidered themselves ‘change agents’:
“One of my guys was just amazed that somebody did
want to talk about his asthma.” (FG1-3)
“I found that middle-aged men . . . were the least
cooperative . . . least likely to make a good effort on the
spirometry and all that kind of thing. But in the end
they did, because . . . they did actually see
improvement . . . they actually became more
enthusiastic about the spirometry.” (FG3-2)
A common theme, for those patients who engaged
with the program, was improved asthma control and
improved understanding of the condition. Pharmacists
proudly reported positive feedback from their study
patients as health improvements became apparent, and
this patient feedback was key to the pharmacists’ motiv-
ation and professional satisfaction throughout the ser-
vice delivery:
“They hadn’t been to an asthma educator . . . and they
find [the service] really, really useful in terms of
understanding inhaler technique and . . . goal setting.”
(FG2-N4)
“One of the ladies I found quite interesting . . . through
discussion, we found out that she was probably an . . .
ibuprofen-sensitive asthmatic. We’ve got her off it,
we’ve got her onto another anti-inflammatory, and
she’s been great ever since . . . so she’s kind of been
singing our praises, which is kind of nice.” (I2-V5)
The variable nature of asthma control and commit-
ment by patients resulted in some challenges for the
pharmacists, suggesting the need for longer-term in-
volvement with at-risk patients:
“One of my patients . . . gave up smoking, and
everything improved. Then for the final visit,
everything was downhill again.”
(FG3-4)
“Often, you’d do the spirometry and they’d be okay,
but . . . they would then deteriorate and possibly even
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time.” (FG3-4)
“Some of my results I think were a bit skewed because
of . . . dust storms or winter or whatever. Some people
with asthma deteriorated, when I would have hoped it
would improved as a result of PAMS . . . as the study
progressed, I realised I was probably out of my depth
with them.” (FG3-1)
Professional rewards
Satisfaction from enhanced clinical practice and empathy
were evident in pharmacists’ reflections on their involve-
ment, even early in the program:
“I really enjoy these programs because it’s a side of
your professional career that you don’t get to ‘do’ very
often.” (FG3-5)
“I suppose it’s really brought asthma into focus in our
pharmacy . . . we are a lot more focused on helping
people with their inhaler technique and checking
whether devices are appropriate for people.” (FG1-5)
“I think I’m far more attuned to them [people with
asthma] and I think I can communicate well with
them because I think I know where they’re coming
from.” [FG3-7]
There were also changes that reportedly occurred in
the pharmacy business as a result of the service, such as
patients committing to the pharmacy’s smoking cessa-
tion program and a perception of greater client loyalty.
The future
Although there were no clear trends between the three
phases of data collection, a number of pharmacists envi-
saged a future for this asthma management service
throughout the trial. Suggestions included extending the
service to children. Practical developments such as allo-
cating a day each week for drop-in consultations, and
the provision of a mobile out-of-hours asthma service,
may address difficulties with issues of patient commit-
ment. Further, reduction in the research-related docu-
mentation would shorten the initial consultation and
enhance efficiency. The pharmacists’ support was exem-
plified by:
“I would like to continue with it for a lot of reasons. It
fulfils a professional need in me, and I like it in that
respect. It can be seen by people as a professional
service.” (FG2-N3)
“We’ve got to put into people’s minds that pharmacy
can provide other types of services . . . part of that is
all about public relations; part of that is to provide a
service and kick it around for a while until we find out
what works and what doesn’t work.” (FG2-N3)A concern for the unmet needs of asthma patients
founded comments about sustaining the program:
“There’s no-one better placed to pick up poorly-
controlled asthmatics than pharmacy.” [FG3-6]
A future for the program would depend on an estab-
lished remuneration process for the pharmacists. Phar-
macists favoured a patient co-payment system so that
consumers would be required to contribute towards the
costs of its provision (and therefore associate a monetary
value to the service), and yet it would remain affordable
to the majority if it were Government-subsidised. An al-
ternative suggestion was to involve other types of practi-
tioners, such as nurse practitioners, in this service.
Discussion
This paper explores pharmacists’ experiences as service
providers in an implementation trial of a novel
evidence-based patient-focused specialist asthma service.
We have elicited their views on recruitment to the ser-
vice, how their patients received the service, interactions
with other health care professionals, particularly general
practitioners, the impact of the service on their role, and
their opinions on offering such a service in future. A
number of the pharmacists expressed what we perceived
would be long-term improvements to their professional
services (e.g. developing a habit of checking inhaler tech-
nique) or a desire to adopt this as an on-going service.
The pharmacists involved in this trial could be consid-
ered ‘early adopters’, [14,15] and their engagement with a
new style of practice provided insight into challenges
and enablers [18] for extended pharmacy services.
Our data were collected predominantly through focus
groups, supplemented by individual interviews for the
participants’ convenience. The combination of methods
balanced the richness of in-depth individual reflections
with data gained from group discussion [21]. The inter-
viewers and focus group facilitators were members of
the academic research team. While the value of an inde-
pendent facilitator in feedback studies is recognised [22],
the direct involvement of the academic researchers in
the data collection ensured familiarity with the protocol
by the interviewers, and allowed immediate feedback to
be given to the pharmacists to clarify the study protocol.
The pharmacists, on the whole, reported positive
experiences with the program for themselves, their phar-
macies, and their asthma patients. This is consistent
with an Australian trial of pharmacists’ involvement in
the prevention of cardiovascular disease, [10] and sug-
gests a future for pharmacists’ engagement in disease
state management services. The pharmacists themselves
envisaged a future for the service, with some specific
needs, such as remuneration and inter-professional
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found experience with structured patient consultations
and associated documentation should benefit their on-
going practice, regardless of the future of this specific
service in their pharmacy.
There are numerous insights from the pharmacists’
reflections on their experience of the asthma service that
demonstrate they have been considering how they might
continue to implement the service on completion of the
study. Some pharmacists expressed regret at the expedi-
ent manner in which they recruited patients for the
study, and proposed different methods of recruitment
that allowed them to target specific patients as they pre-
sented. A frequently expressed theme was the desire to
expand the service to children. Pharmacists also
reflected on the variable nature of asthma and therefore
the need for an ongoing service. This, coupled with
strongly expressed professional satisfaction, indicated
that this group of pharmacists had developed the neces-
sary elements to offer a sustainable asthma service.
The fundamental nature of the service required phar-
macists to act as an intermediary between patients and
prescribers. A number of pharmacists were challenged
clinically by complex patient cases, testament to the
need for collaboration between pharmacists and GPs for
such patients. The extent of this collaboration, however,
was often less than ideal, consistent with research con-
ducted into pharmacist-GP relationships in Australia,
[23] which reported a “generally favourable attitude to-
wards one another” but “limited understanding/confi-
dence in the breadth of knowledge of their cross-
disciplinary colleagues” and Canada, in which GPs was
perceived as “gatekeepers controlling patients’ access to
pharmacy services that are unrelated to dispensing [18]”.
Pharmacists in our study also reported variable commit-
ment to the program by some patients (working people
and younger patients), presumed due to undervaluing of
the service by these patients, inability for the organisa-
tion and delivery of the service to meet their needs, and/
or the lengthy consultations associated with research
documentation. Despite this, numerous comments
reflected significant professional satisfaction gained
through enhanced patient interaction and improved
health outcomes. As in an earlier study of inhaler tech-
nique education, [24] these positive experiences led
some pharmacists to apply skills and tools acquired dur-
ing the study to non-study patients.
The pharmacists were required to adopt a research
culture and to commit to being pioneers of a new pro-
fessional initiative. Few, if any, of the pharmacists would
have received formal university training on research or
evidence-based practice, and their involvement in this
program was an opportunity for them to provide a
structured service independently, yet under guidance ofacademic researchers. The ‘hand holding’ was a feature
of the study design, as it was expected that engagement
of the pharmacists with the academic researchers would
be key to their commitment to this project. It should be
noted that the nature of the researchers’ support was op-
erational, without clinical judgement or input into the
patient cases managed by the pharmacists. The training
and credentialing ensured that the pharmacists were in-
dividually clinically competent, and were empowered to
continue providing this service following the conclusion
of the study.
Pharmacists’ comments regarding spirometry as a
highlight of the training day, and requesting more train-
ing in spirometry measurement and interpretation, likely
reflect the extension of their knowledge and skills in a
related but normally unfamiliar area. This, coupled with
their reflections on participants’ interest in exploring
their own spirometry results, demonstrate the ability of
spirometry to facilitate engagement between patients
and health practitioners on asthma and other respiratory
disease management. The inclusion of spirometry (or in-
deed, any diagnostic procedure requiring the pharma-
cist’s involvement) limits this type of service to face-to-
face consultations, which further engages the patient in
a direct care relationship with the health practitioner.
The low rate (9 %) of spirometry measurement at gen-
eral practice encounters for the management of asthma
in Australia [25], despite annual measurement being
recommended, indicates the importance of expanding
the range of health professionals who are competent at
spirometry measurement, with pharmacists being ideally
placed to offer this service. Future iterations of this
asthma management service could focus more on the
fluctuations of asthma control, and the visits could be
tailored accordingly. Pharmacists must be cognisant of
how fluctuations appear in spirometry measurements
and the level of asthma control, to be expected to re-
spond with appropriate medication.
One limitation in our approach is that, despite the use
of three time points for pharmacists’ feedback, we did
not longitudinally monitor each pharmacist’s experi-
ences. Further, the lack of commitment or availability of
younger patients and greater enthusiasm of older
patients, as reported by a number of pharmacists, may
have influenced the pharmacists’ experiences with this
trial. Finally, the pharmacists may have felt “obliged” to
give positive feedback to the facilitator. To minimise this
response bias, for the focus groups, one member of the
team whom they had not met in training and had not
visited them at their pharmacy was the facilitator. We
found that the elucidation of ambivalent and negative
experiences (“disconfirming evidence”) [26], particularly
regarding the study workload, suggested that the focus
groups did not foster ‘normalisation’ or tempering of the
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discussions were facilitated in a supportive environment.
Similar experiences were reported by researchers in
trials of diabetes management services in Australia.
[8,13]
We have derived a number of recommendations for
optimal involvement of pharmacists in a multi-centre
academic research trial of this nature, and therefore to
inform wider implementation of this asthma service and
design of trials for other services:
 The pharmacists should be provided comprehensive
training in their areas of need (e.g. skills in
spirometry, communication with GPs), with
credentialing to ensure competence.
 The training component of the service should
involve training in the research requirements
(specifically patient recruitment, consultation and
documentation) and the physical requirements for
provision of professional services (work flow,
staffing, appointment systems and the consultation
area).
 Research-related paperwork and data collection
should be minimised.
 The researchers should provide support in the
communication and feedback with/by the
investigators, and via site visits, to enhance the
pharmacists’ confidence and engagement; the
interaction should be managed carefully to preserve
the relationship between the pharmacists and
academic researchers.
 Balance is required between imposing on the
pharmacists a structured research protocol,
providing operational support for their involvement,
and affording them the flexibility to manage
individual patients.
 The researchers should acknowledge that despite
the pharmacists’ commitment to research, the core
businesses of community pharmacy will be their
priority.
 The opportunity for involvement in research can be
promoted to pharmacists as a business model in
terms of investments (training, workplace support)
and returns (improved patient outcomes and
loyalty).
Pharmacists’ involvement in an academically-managed
trial of a new service is likely to have benefits reaching
more broadly than to the select patient cohort under
study. Further, it is hoped that by engaging with the
pharmacists as research partners, and instilling a re-
search culture into community pharmacy practice, this
study has generated goodwill for future pharmacy-based
research initiatives.Conclusions
The feedback from the study pharmacists was positive
overall, yet constructively critical of some aspects of the
research protocol, which was not surprising considering
the volume of research data being collected. The phar-
macists were engaged as research partners, recognising
their role as pioneers of a novel, clinically advanced ser-
vice model for other Australian pharmacists. They
understood the need for the service and were able to
give valuable feedback about its future. Key challenges
for the pharmacists related to recruitment of asthma
patients, time management, and collaboration with GPs.
Overall, their positive experiences demonstrated that if
the challenges were managed strategically, implementa-
tion of such a service model would be possible.
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